PT-141

Research Use Only: This page is for research and educational purposes only. It does not provide medical advice, treatment instructions, or guaranteed outcome claims.

What Is PT-141?

If your query is what is pt-141, the practical answer is: PT-141 (bremelanotide), marketed under the brand name Vyleesi®, is a synthetic cyclic heptapeptide and melanocortin receptor agonist investigated primarily in libido and sexual function research contexts. In June 2019, it became the first and only FDA-approved on-demand melanocortin agonist for hypoactive sexual desire disorder (HSDD) in premenopausal women — a mechanism class entirely distinct from peripheral vasodilators like PDE5 inhibitors.[4][7]

PT-141 peptide (also written as PT 141 peptide, PT 141, pt-141 peptide, or bremelanotide peptide) was derived from Melanotan II (MT-II), a synthetic analog of α-melanocyte-stimulating hormone (α-MSH). However, the two compounds are structurally and functionally distinct: PT-141 is the active metabolite of MT-II, engineered without melanogenic (tanning) activity. Where MT-II activates all five melanocortin receptor subtypes — producing skin pigmentation alongside other effects — bremelanotide selectively targets MC3R and MC4R in the hypothalamus, modulating neural pathways involved in sexual arousal and desire without skin-darkening effects.[1]

This page covers the evidence as it actually exists: FDA-approved clinical trial data for premenopausal HSDD, the melanocortin mechanism of action, and the practical limits of current research. For broader context, see the Libido & Sexual Function and Testosterone / Hormonal Support goal pages.

Compound Profile

The PT 141 peptide compound profile above summarises the key pharmacological parameters established through clinical development and FDA regulatory review.

What Does PT-141 Actually Do?

Most bremelanotide peptide discussion centres on one practical distinction: PT-141 operates centrally — in the brain — rather than peripherally in vascular tissue. This is fundamentally different from how PDE5 inhibitors (sildenafil, tadalafil) work. Those compounds increase blood flow to peripheral tissues. PT-141 instead activates melanocortin receptors in the hypothalamus, modulating the neural circuitry that governs sexual desire and arousal at its origin point.[1]

In practical terms, this means bremelanotide targets the desire component of sexual function — the central nervous system pathways that initiate arousal — rather than the mechanical component of blood flow and tissue response. This distinction is why PT-141 was investigated specifically for hypoactive sexual desire disorder (HSDD), a condition characterised by persistently low sexual desire causing distress, rather than for erectile dysfunction or arousal disorders with purely vascular origins.[2][4]

The melanocortin pathway itself is one of the brain’s core regulatory systems, involved in appetite, energy balance, inflammation, and neuroendocrine signalling. PT-141’s specificity for the MC3R and MC4R subtypes within this system is what gives it a relatively targeted sexual function profile compared to broader melanocortin agonists like Melanotan II, which activates all five receptor subtypes.[1]

How PT-141 Works

To understand PT 141 how does it work requires examining the molecular detail. Bremelanotide’s mechanism of action centres on activation of melanocortin-3 (MC3R) and melanocortin-4 (MC4R) receptors in the medial preoptic area and paraventricular nucleus of the hypothalamus. These regions are critical integration hubs for sexual motivation, connecting sensory input, hormonal status, and emotional context into behavioural output. When PT-141 binds these receptors, it initiates downstream signalling cascades that modulate dopaminergic and oxytocinergic pathways — two neurotransmitter systems directly implicated in sexual desire, reward, and pair-bonding behaviour.[1]

The α-MSH pathway provides the natural context. Alpha-melanocyte-stimulating hormone is an endogenous neuropeptide that activates melanocortin receptors as part of normal neuroendocrine signalling. PT-141, as a synthetic analog of α-MSH (via its parent compound MT-II), mimics this natural activation with greater receptor selectivity and metabolic stability. The result observed in clinical research is enhanced central arousal signalling without the peripheral vascular changes that characterise PDE5 inhibitor activity.[1][7]

Importantly, this central mechanism means PT-141’s observed effects are not dependent on peripheral blood flow enhancement. In the RECONNECT Phase 3 trials, the primary endpoint measured was the change in the Female Sexual Function Index (FSFI) desire domain score and the Female Sexual Distress Scale (FSDS-DAO) — measures of subjective desire and associated distress, not physiological arousal metrics.[2] This aligns with the mechanistic prediction: a compound acting on hypothalamic desire circuits should improve desire-related endpoints rather than vascular arousal markers.

Libido & Sexual Function Context

Libido and sexual function research represents PT-141’s primary evidence domain — and the only context in which it has achieved regulatory approval. The RECONNECT programme comprised two randomised, double-blind, placebo-controlled Phase 3 trials enrolling over 1,200 premenopausal women with HSDD. Both trials demonstrated statistically significant improvements in sexual desire (FSFI desire domain) and reductions in distress associated with low desire (FSDS-DAO) compared to placebo, leading directly to FDA approval.[2]

Long-term data from the open-label extension study (Simon 2019) followed participants for up to 18 months, providing the longest continuous safety and efficacy dataset for bremelanotide. Results showed sustained efficacy without tachyphylaxis — meaning the compound did not lose effectiveness over repeated administration — alongside a consistent safety profile dominated by nausea as the most common adverse event.[3] The FDA approval review (Dhillon & Keam 2019) contextualised these findings within the broader HSDD treatment landscape, noting that bremelanotide’s on-demand, non-hormonal profile offered a mechanistically distinct option from flibanserin (Addyi®), the only other FDA-approved HSDD treatment, which requires daily administration and acts on serotonin receptors.[4]

PT 141 for women was the clinical focus of this entire programme, and the Vyleesi FDA approval established bremelanotide as the first on-demand melanocortin-based option specifically for female HSDD. The evidence confidence for this domain is moderate-high: Phase 3 RCT data, FDA regulatory review, and long-term follow-up data collectively provide a robust evidence base, though limited to a specific population (premenopausal women with generalised acquired HSDD). Earlier exploratory research (Diamond 2006) had also demonstrated effects on subjective sexual response in premenopausal women with sexual arousal disorder, providing directional preclinical-to-clinical continuity.[6]

Testosterone / Hormonal Support Context

PT-141 does not directly modulate testosterone synthesis, secretion, or receptor activity — and should not be characterised as a hormonal compound in the traditional sense. However, its inclusion in the testosterone / hormonal support research context reflects the melanocortin system’s broader role in neuroendocrine regulation. MC3R and MC4R receptors participate in signalling networks that interact with the hypothalamic-pituitary-gonadal (HPG) axis, the central regulatory pathway for sex hormone production.[1]

The distinction is important: bremelanotide acts upstream of hormonal endpoints, modulating central pathways that interact with — but do not directly constitute — the hormonal signalling cascade. In preclinical models, melanocortin system activation has been observed to influence luteinising hormone (LH) pulsatility and gonadotropin-releasing hormone (GnRH) signalling, both of which sit upstream of testosterone production. However, these observations have not been systematically investigated in clinical PT-141 research, and the compound’s clinical development focused exclusively on sexual desire endpoints rather than hormonal biomarkers.

For researchers interested in the intersection of melanocortin signalling and hormonal regulation, PT-141 represents a relevant but indirect data point. The compound’s mechanism confirms that central melanocortin activation can influence sexually-relevant neural circuits, but the pathway from MC3R/MC4R activation to measurable hormonal changes remains an area of ongoing investigation rather than established clinical evidence. Compounds like Sermorelin, CJC-1295, and Ipamorelin offer more direct endocrine pathway research for those specifically interested in hormonal modulation.

PT-141 Benefits

PT 141 benefits are grounded in its unique central mechanism of action. Research-supported observations associated with bremelanotide in clinical investigation include:

• Central mechanism of action — operates at the neural origin of sexual desire (hypothalamus) rather than peripheral vascular tissue, addressing the desire component directly.[1]
• FDA-approved pedigree — one of only two FDA-approved compounds for HSDD, and the only on-demand option with a melanocortin mechanism.[4][7]
• Non-hormonal mechanism — does not modulate estrogen, progesterone, or testosterone levels directly, offering a mechanistically distinct profile from hormonal interventions.
• On-demand pharmacokinetic profile — rapid onset (~1 hour to peak plasma) with moderate duration, investigated as an as-needed compound rather than requiring daily administration.[3]
• Phase 3 RCT evidence — efficacy demonstrated across two large randomised controlled trials (RECONNECT) with statistically significant improvements in desire and distress endpoints.[2]
• Sustained efficacy — long-term open-label extension data showed maintained response without evidence of tachyphylaxis over 18 months.[3]
• Mechanistic distinction from PDE5 inhibitors — entirely different target pathway from sildenafil/tadalafil, relevant for contexts where vascular interventions are inappropriate or insufficient.

PT-141 Side Effects

PT 141 side effects are well-characterised from Phase 3 clinical trials and the open-label extension study. The profile is tiered below by evidence confidence:

Well-documented (Phase 3 RCT data):

• Nausea — the most commonly reported adverse event, observed in approximately 40% of participants in clinical trials. Most episodes were mild-to-moderate and decreased with repeated administration.[2][3]
• Flushing — reported in approximately 20% of trial participants, consistent with melanocortin receptor activation and vasomotor effects.[2]
• Injection site reactions — localised erythema, pain, or induration at the administration site, typical of subcutaneous peptide research.[3]
• Headache — reported in a subset of participants across both RECONNECT trials.[2]

Observed in clinical monitoring:

• Transient blood pressure changes — ambulatory blood pressure monitoring studies (White 2017) documented small, transient increases in systolic blood pressure following administration. These changes were generally not clinically significant in normotensive participants but represent a monitoring consideration.[5]

Monitoring considerations:

• Skin hyperpigmentation — rare but reported, consistent with melanocortin receptor activation. Unlike Melanotan II, PT-141 was engineered to minimise melanogenic activity, but low-level MC1R interaction cannot be fully excluded.[4]

Half-Life

PT-141 has a plasma half-life of approximately 2.5 hours, placing it in the on-demand pharmacokinetic category rather than the sustained-release or depot profiles seen with compounds like CJC-1295 with DAC or semaglutide. Peak plasma concentration is reached approximately 1 hour after subcutaneous administration, with the onset of observed effects typically reported within 45 minutes to 1 hour in clinical trial protocols.[4][7]

This pharmacokinetic profile informed the clinical trial design: in the RECONNECT programme, bremelanotide was investigated as an as-needed compound administered approximately 45 minutes before anticipated sexual activity, with a recommended minimum interval of 24 hours between administrations. The relatively rapid clearance supports the on-demand framing — effects are temporally bounded rather than continuous, distinguishing PT-141 from daily-administration compounds like flibanserin.[2][3]

For researchers evaluating peptide pharmacokinetics, the ~2.5-hour half-life positions bremelanotide between very short-acting peptides (e.g., natural GnRH, ~2-4 minutes) and longer-acting modified peptides. The cyclic heptapeptide structure provides sufficient metabolic stability for clinically meaningful duration without requiring half-life extension modifications like PEGylation or albumin binding.

Limits of Current Evidence

Despite FDA approval, PT-141’s evidence base has specific boundaries that contextualise its research utility:

• Narrow approved indication — FDA approval covers premenopausal women with generalised acquired HSDD only. Postmenopausal women, men, and other sexual function contexts are not covered by the regulatory evidence package.[4]
• Male erectile dysfunction data is limited — early-phase studies investigated bremelanotide for male erectile dysfunction, but the clinical programme did not advance to Phase 3 for this indication. PT 141 for men remains an area of preliminary evidence, with male sexual function research still in the early-phase tier.[6]
• High nausea rate — the ~40% nausea incidence in trials is notable and represents a practical limitation for research applicability, even though most episodes were mild-to-moderate.[2][3]
• Limited long-term post-market data — the open-label extension provides 18-month safety data, but decades of post-marketing surveillance data (as exists for older compounds like sermorelin) is not yet available.[3]
• No head-to-head trials vs flibanserin — despite both compounds having FDA approval for HSDD, no published randomised controlled trial directly compares bremelanotide to flibanserin on efficacy or tolerability endpoints.
• Effect size scrutiny — independent re-analysis of HSDD trial methodologies (Diamond 2006, subsequent meta-analytic discussions) has raised questions about clinical meaningfulness of statistically significant effect sizes in desire endpoints, a broader methodological consideration across the HSDD field.[6]
• No data outside sexual function — while the melanocortin system has broad research interest (inflammation, neuroprotection, energy balance), PT-141 has not been clinically investigated for these applications.

Verdict

In this PT 141 review of the clinical evidence, PT-141 (bremelanotide) occupies a unique position in the peptide research landscape: it is the only FDA-approved on-demand melanocortin agonist for sexual desire, with a central mechanism of action that distinguishes it from every peripheral treatment in the sexual function space. The RECONNECT Phase 3 programme and subsequent FDA approval provide a level of regulatory validation uncommon among research peptides, and the long-term extension data adds 18 months of sustained efficacy and safety evidence.[2][3][4]

That said, the evidence base is narrower than the compound’s mechanism might suggest. Approval is limited to a specific population (premenopausal women with HSDD), the ~40% nausea rate is clinically significant, and research outside sexual function remains minimal. For the melanocortin pathway itself — which intersects with hormonal signalling, neuroprotection, and metabolic regulation — PT-141 represents a validated proof-of-concept that central melanocortin activation can modulate sexually-relevant neural circuits, even if its clinical application remains focused.

For researchers evaluating the libido and sexual function evidence landscape, bremelanotide provides the strongest regulatory evidence for central desire modulation currently available. Its mechanistic distinction from PDE5 inhibitors and serotonergic compounds (flibanserin) makes it a reference compound for understanding how hypothalamic melanocortin signalling translates to clinical sexual function outcomes. The compound is best understood as a focused, well-validated tool within a specific research domain rather than a broad-spectrum peptide with multi-system applications.

For researchers exploring related compounds, tirzepatide and semaglutide represent FDA-approved peptides in the metabolic space, while BPC-157 and TB-500 are studied in tissue repair contexts. GHK-Cu shares melanocortin-adjacent research interest through its role in signalling peptide biology, and tesamorelin represents another FDA-approved peptide with hormonal research relevance.

FAQ

What is PT-141 (bremelanotide)?

For anyone asking “what is PT 141,” the answer is straightforward: PT-141, also known as bremelanotide and marketed as Vyleesi®, is a synthetic cyclic heptapeptide that activates melanocortin-3 and melanocortin-4 receptors (MC3R/MC4R) in the brain. It was approved by the FDA in June 2019 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women, making it the first on-demand melanocortin agonist approved for this indication.[4][7]

How does PT-141 work differently from Viagra?

PT-141 and Viagra (sildenafil) operate through entirely different mechanisms. Viagra is a PDE5 inhibitor that increases blood flow to peripheral tissues — it works on the vascular system. PT-141 activates melanocortin receptors in the hypothalamus, modulating the neural pathways that govern sexual desire at the brain level. In simple terms, PT-141 targets desire (central) while Viagra targets blood flow (peripheral).[1]

Is PT-141 FDA approved?

Yes. Bremelanotide (Vyleesi®) received FDA approval in June 2019 specifically for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. This approval was based on the RECONNECT Phase 3 clinical trial programme, which included two large randomised controlled trials demonstrating statistically significant improvements in desire and distress endpoints.[2][4]

What are the side effects of PT-141?

The most commonly reported side effect in clinical trials was nausea, observed in approximately 40% of participants. Other reported adverse events included flushing (~20%), injection site reactions, and headache. Transient blood pressure changes were documented in ambulatory monitoring studies but were generally not clinically significant in normotensive individuals.[2][3][5]

Is PT-141 the same as Melanotan II?

No. While PT-141 (bremelanotide) was derived from Melanotan II (MT-II) and shares a related peptide backbone, they are structurally and functionally distinct compounds. MT-II activates all five melanocortin receptor subtypes, producing skin tanning (melanogenesis) alongside other effects. PT-141 is the active metabolite of MT-II, engineered to selectively target MC3R/MC4R without melanogenic activity — meaning it does not cause tanning. The key distinction in any PT 141 vs Melanotan comparison is this receptor selectivity: PT-141 targets MC3R/MC4R for sexual function without the skin-darkening effects associated with MT-II’s broader MC1R activation.[1]

Does PT-141 work for men?

Early-phase clinical research investigated bremelanotide for male erectile dysfunction and showed some positive signals in preliminary studies.[6] However, the clinical development programme for male indications did not advance to Phase 3 trials, and PT-141’s FDA approval is limited to premenopausal women with HSDD. Male sexual function research with bremelanotide remains in the preliminary evidence tier.

How long does PT-141 take to work?

In clinical trial protocols, bremelanotide reached peak plasma concentration approximately 1 hour after subcutaneous administration, with onset of observed effects typically reported within 45 minutes to 1 hour. The compound has a plasma half-life of approximately 2.5 hours, supporting its on-demand pharmacokinetic profile.[4][7]

References

1. Pfaus JG, et al. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectr. 2022;27(3):281-295. PMID: 33455598
2. Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. PMID: 31599840
3. Simon JA, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019;134(5):909-917. PMID: 31599847
4. Dhillon S, Keam SJ. Bremelanotide: First Approval. Drugs. 2019;79(14):1599-1606. PMID: 31429064
5. White WB, et al. Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide. J Hypertens. 2017;35(4):761-767. PMID: 27977473
6. Diamond LE, et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141). J Sex Med. 2006;3(4):628-638. PMID: 16839319
7. Mayer D, Lynch SE. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder. Ann Pharmacother. 2020;54(7):684-690. PMID: 31893927